Calogero Catanzaro, Natali Rodriguez Peñaranda, Andrea Marmiroli, Mattia Longoni, Quynh Chi Le, Fabian Falkenbach, Michele Nicolazzini, Jordan A Goyal, Lorenzo Bianchi, Pietro Piazza, Angelo Mottaran, Fred Saad, Shahrokh F Shariat, Salvatore Micali, Gennaro Musi, Alberto Briganti, Felix K H Chun, Markus Graefen, Alessandro Volpe, Riccardo Schiavina, Pierre I Karakiewicz
{"title":"炎症性肠病与根治性前列腺切除术后的不良住院结果","authors":"Calogero Catanzaro, Natali Rodriguez Peñaranda, Andrea Marmiroli, Mattia Longoni, Quynh Chi Le, Fabian Falkenbach, Michele Nicolazzini, Jordan A Goyal, Lorenzo Bianchi, Pietro Piazza, Angelo Mottaran, Fred Saad, Shahrokh F Shariat, Salvatore Micali, Gennaro Musi, Alberto Briganti, Felix K H Chun, Markus Graefen, Alessandro Volpe, Riccardo Schiavina, Pierre I Karakiewicz","doi":"10.1016/j.urolonc.2025.07.032","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The effect of inflammatory bowel disease (IBD) on adverse in-hospital outcomes after radical prostatectomy (RP) for nonmetastatic prostate cancer (PCa) is not well known.</p><p><strong>Materials and methods: </strong>Descriptive analyses, propensity score matching and multivariable logistic regression models were used within the National Inpatient Sample (2000-2019) RP patients, after stratification according to Crohn's disease (CD) vs. ulcerative colitis (UC) vs. no-IBD, and RP type (minimally invasive [MIRP] vs. open [ORP]).</p><p><strong>Results: </strong>Of 251,334 RP patients, 486 (0.2%) had CD vs. 446 (0.2%) UC. In CD patients vs. no-IBD counterparts, MIRP (n = 223) independently predicted higher rates of adverse in-hospital outcomes in 3/15 categories, including overall (OR:1.64, P < 0.01) and postoperative (OR:1.73, P < 0.01) complications. Conversely, in CD patients vs. no-IBD counterparts, ORP (n = 263) independently predicted higher rates of adverse in-hospital outcomes in 5/15 categories, including also overall (OR:1.37, P < 0.05), and postoperative (OR:1.44, P < 0.05) complications. In UC patients vs. no-IBD counterparts, MIRP (n = 218) independently predicted higher rates of adverse in-hospital outcomes in only 1/15 categories, namely prolonged length of stay (OR:1.64, P < 0.001). Conversely, in UC patients vs. no-IBD counterparts, ORP (n = 228) independently predicted higher rates of adverse in-hospital outcomes in 3/15 categories, including overall (OR:1.49, P < 0.05) and intraoperative (OR:2.31, P < 0.01) complications.</p><p><strong>Conclusion: </strong>In the current analysis, direct comparisons with no-IBD patients showed worse in-hospital outcomes for both CD and UC patients, with adverse in-hospital outcomes indirectly appearing more severe in CD than in UC patients. In both subgroups, MIRP was associated with fewer adverse outcomes than ORP, based on comparison with no-IBD patients.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Inflammatory bowel disease vs. adverse in-hospital outcomes after radical prostatectomy.\",\"authors\":\"Calogero Catanzaro, Natali Rodriguez Peñaranda, Andrea Marmiroli, Mattia Longoni, Quynh Chi Le, Fabian Falkenbach, Michele Nicolazzini, Jordan A Goyal, Lorenzo Bianchi, Pietro Piazza, Angelo Mottaran, Fred Saad, Shahrokh F Shariat, Salvatore Micali, Gennaro Musi, Alberto Briganti, Felix K H Chun, Markus Graefen, Alessandro Volpe, Riccardo Schiavina, Pierre I Karakiewicz\",\"doi\":\"10.1016/j.urolonc.2025.07.032\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The effect of inflammatory bowel disease (IBD) on adverse in-hospital outcomes after radical prostatectomy (RP) for nonmetastatic prostate cancer (PCa) is not well known.</p><p><strong>Materials and methods: </strong>Descriptive analyses, propensity score matching and multivariable logistic regression models were used within the National Inpatient Sample (2000-2019) RP patients, after stratification according to Crohn's disease (CD) vs. ulcerative colitis (UC) vs. no-IBD, and RP type (minimally invasive [MIRP] vs. open [ORP]).</p><p><strong>Results: </strong>Of 251,334 RP patients, 486 (0.2%) had CD vs. 446 (0.2%) UC. In CD patients vs. no-IBD counterparts, MIRP (n = 223) independently predicted higher rates of adverse in-hospital outcomes in 3/15 categories, including overall (OR:1.64, P < 0.01) and postoperative (OR:1.73, P < 0.01) complications. Conversely, in CD patients vs. no-IBD counterparts, ORP (n = 263) independently predicted higher rates of adverse in-hospital outcomes in 5/15 categories, including also overall (OR:1.37, P < 0.05), and postoperative (OR:1.44, P < 0.05) complications. In UC patients vs. no-IBD counterparts, MIRP (n = 218) independently predicted higher rates of adverse in-hospital outcomes in only 1/15 categories, namely prolonged length of stay (OR:1.64, P < 0.001). Conversely, in UC patients vs. no-IBD counterparts, ORP (n = 228) independently predicted higher rates of adverse in-hospital outcomes in 3/15 categories, including overall (OR:1.49, P < 0.05) and intraoperative (OR:2.31, P < 0.01) complications.</p><p><strong>Conclusion: </strong>In the current analysis, direct comparisons with no-IBD patients showed worse in-hospital outcomes for both CD and UC patients, with adverse in-hospital outcomes indirectly appearing more severe in CD than in UC patients. In both subgroups, MIRP was associated with fewer adverse outcomes than ORP, based on comparison with no-IBD patients.</p>\",\"PeriodicalId\":23408,\"journal\":{\"name\":\"Urologic Oncology-seminars and Original Investigations\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-09-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urologic Oncology-seminars and Original Investigations\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.urolonc.2025.07.032\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologic Oncology-seminars and Original Investigations","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.urolonc.2025.07.032","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
简介：炎性肠病（IBD）对非转移性前列腺癌（PCa）根治性前列腺切除术（RP）后不良住院结果的影响尚不清楚。材料和方法：根据克罗恩病（CD）与溃疡性结肠炎（UC）与非ibd以及RP类型（微创[MIRP]与开放式[ORP]）进行分层后，对全国住院患者样本（2000-2019）RP患者进行描述性分析、倾向评分匹配和多变量logistic回归模型。结果：在251,334例RP患者中，486例（0.2%）有CD， 446例（0.2%）有UC。与非ibd患者相比，在CD患者中，MIRP （n = 223）独立预测3/15类不良住院结局的发生率更高，包括总体（OR:1.64, P < 0.01）和术后（OR:1.73, P < 0.01）并发症。相反，与非ibd患者相比，在CD患者中，ORP （n = 263）独立预测5/15类别中更高的不良住院结局发生率，包括总体（OR:1.37, P < 0.05）和术后（OR:1.44, P < 0.05）并发症。在UC患者与非ibd患者中，MIRP （n = 218）仅在1/15类别中独立预测更高的不良住院结局发生率，即延长住院时间（OR:1.64, P < 0.001）。相反，UC患者与非ibd患者相比，ORP （n = 228）独立预测3/15类院内不良结局的发生率更高，包括总体并发症（OR:1.49, P < 0.05）和术中并发症（OR:2.31, P < 0.01）。结论：在当前的分析中，与非ibd患者的直接比较显示，CD和UC患者的住院结局更差，CD患者的不良住院结局间接比UC患者更严重。在两个亚组中，基于与非ibd患者的比较，MIRP与ORP相关的不良后果较少。
Inflammatory bowel disease vs. adverse in-hospital outcomes after radical prostatectomy.
Introduction: The effect of inflammatory bowel disease (IBD) on adverse in-hospital outcomes after radical prostatectomy (RP) for nonmetastatic prostate cancer (PCa) is not well known.
Materials and methods: Descriptive analyses, propensity score matching and multivariable logistic regression models were used within the National Inpatient Sample (2000-2019) RP patients, after stratification according to Crohn's disease (CD) vs. ulcerative colitis (UC) vs. no-IBD, and RP type (minimally invasive [MIRP] vs. open [ORP]).
Results: Of 251,334 RP patients, 486 (0.2%) had CD vs. 446 (0.2%) UC. In CD patients vs. no-IBD counterparts, MIRP (n = 223) independently predicted higher rates of adverse in-hospital outcomes in 3/15 categories, including overall (OR:1.64, P < 0.01) and postoperative (OR:1.73, P < 0.01) complications. Conversely, in CD patients vs. no-IBD counterparts, ORP (n = 263) independently predicted higher rates of adverse in-hospital outcomes in 5/15 categories, including also overall (OR:1.37, P < 0.05), and postoperative (OR:1.44, P < 0.05) complications. In UC patients vs. no-IBD counterparts, MIRP (n = 218) independently predicted higher rates of adverse in-hospital outcomes in only 1/15 categories, namely prolonged length of stay (OR:1.64, P < 0.001). Conversely, in UC patients vs. no-IBD counterparts, ORP (n = 228) independently predicted higher rates of adverse in-hospital outcomes in 3/15 categories, including overall (OR:1.49, P < 0.05) and intraoperative (OR:2.31, P < 0.01) complications.
Conclusion: In the current analysis, direct comparisons with no-IBD patients showed worse in-hospital outcomes for both CD and UC patients, with adverse in-hospital outcomes indirectly appearing more severe in CD than in UC patients. In both subgroups, MIRP was associated with fewer adverse outcomes than ORP, based on comparison with no-IBD patients.
期刊介绍：
Urologic Oncology: Seminars and Original Investigations is the official journal of the Society of Urologic Oncology. The journal publishes practical, timely, and relevant clinical and basic science research articles which address any aspect of urologic oncology. Each issue comprises original research, news and topics, survey articles providing short commentaries on other important articles in the urologic oncology literature, and reviews including an in-depth Seminar examining a specific clinical dilemma. The journal periodically publishes supplement issues devoted to areas of current interest to the urologic oncology community. Articles published are of interest to researchers and the clinicians involved in the practice of urologic oncology including urologists, oncologists, and radiologists.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
